Milestone Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Milestone Pharmaceuticals Inc. announced FDA approval for its first commercial product, CARDAMYST nasal spray for PSVT, and is advancing etripamil for AFib-RVR while expanding international regulatory efforts.
NASDAQ
Milestone Pharmaceuticals Inc. announces its 2024 financial results and awaits the FDA's decision on CARDAMYST for PSVT, expected by March 27, 2025.
NASDAQ
10-K/A: Milestone Pharmaceuticals Amends Annual Report, Provides Updated Director and Executive Information
Milestone Pharmaceuticals has amended its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
10-K: Milestone Pharmaceuticals Faces Setback with FDA Rejection, Resubmission Planned for Etripamil
Milestone Pharmaceuticals received a refuse-to-file letter from the FDA for its etripamil NDA, but plans to resubmit in the second quarter of 2024 after addressing data clarification requests.